Feb 28 |
Mersana Therapeutics GAAP EPS of -$0.16 in-line, revenue of $10.7M misses by $4.07M
|
Feb 28 |
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
|
Feb 27 |
Mersana Therapeutics Q4 2023 Earnings Preview
|
Feb 27 |
Mersana Therapeutics to Present at Upcoming Investor Conferences
|
Feb 26 |
Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?
|
Feb 21 |
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024
|
Feb 20 |
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
|
Jan 18 |
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
|
Jan 11 |
Mersana Therapeutics: A Bottom-Feeding Gamble Of A Stock
|
Jan 5 |
Mersana Therapeutics announces business updates, expected 2024 milestones
|